Screener
ImmunityBio, Inc. IBRX Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Classification | March 31, 2026 | December 31, 2025 |
|---|---|---|---|
| Liabilities | |||
| Current: | |||
| Operating lease liabilities (including amounts with related parties) | Operating lease liabilities | $7,626 | $7,535 |
| Finance lease liabilities | Accrued expenses and other liabilities | 53 | 52 |
| Noncurrent: | |||
| Operating lease liabilities (including amounts with related parties) | Operating lease liabilities, less current portion | 33,147 | 33,447 |
| Finance lease liabilities | Other liabilities | 213 | 227 |
| Total lease liabilities (including amounts with related parties) | $41,039 | $41,261 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s operating lease liabilities?
- ImmunityBio, Inc. (IBRX) reported operating lease liabilities of $33.15M in Q1 2026.
- How has ImmunityBio, Inc.'s operating lease liabilities changed year-over-year?
- ImmunityBio, Inc.'s operating lease liabilities increased by 0.2% year-over-year, from $33.1M to $33.15M.
- What is the long-term trend for ImmunityBio, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s operating lease liabilities has grown at a 15.6% compound annual growth rate (CAGR), from $16.18M to $33.45M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about ImmunityBio, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude